Manchin v. PACS Group, Inc.

District Court, S.D. New York·Decided May 1, 2025·No. 1:24-cv-08636·Unknown

Opinion

USDC SDNY DOCUMENT UNITED STATES DISTRICT COURT ELECTRONICALLY FILED SOUTHERN DISTRICT OF NEW YORK DOC #: ncaa cnns cannes ncnnc cnnccacnnccccnnnn DATE FILED: __5/2/2025 CHRISTOPHER MANCHIN, individually and on : behalf of all others similarly situated, : Plaintiff, : -v- : 24-cv-8636 (LJL) PACS GROUP, INC., JASON MURRAY, DERICK : OPINION AND ORDER APT, MARK HANCOCK, JACQUELINE MILLARD, : TAYLOR LEAVITT, CITIGROUP GLOBAL : MARKETS INC., J.P. MORGAN SECURITIES LLC, — : TRUIST SECURITIES, INC., RBC CAPITAL : MARKETS, LLC, GOLDMAN SACHS & CO. LLC, : STEPHENS INC., KEYBANC CAPITAL MARKETS — : INC., OPPENHEIMER & CO. INC., and REGIONS : SECURITIES LLC, : Defendants. : wee KX

LEWIS J. LIMAN, United States District Judge: Defendants PACS Group, Inc. (“PACS”) and Jason Murray, Derick Apt, Mark Hancock, Michelle Lewis, Jacqueline Millard, Taylor Leavitt, and Evelyn Dilsaver (the “Individual Defendants” and with PACS, “Moving Defendants”) move, pursuant to 28 U.S.C. § 1404(a), for an order transferring this consolidated action to the United States District Court for the District of Utah. Dkt. No. 47. The motion 1s joined by Defendants Citigroup Global Markets Inc., J.P Morgan Securities LLC, Truist Securities, Inc., RBC Capital Markets, LLC, Goldman Sachs & Co. LLC, Stephens Inc., KeyBank Capital Markets Inc., Oppenheimer & Co. Inc., Regions Securities LLC, and UBS Securities, LLC (the “Underwriter Defendants”). Dkt. No. 51. For the reasons that follow, the motion to transfer is DENIED.

BACKGROUND For the purposes of this motion, the Court accepts as true the allegations in the complaints filed in Manchin v. PACS Group, Inc., No. 24-cv-8636 (S.D.N.Y) (“Manchin”), Dkt. No. 1 (“Manchin Compl.”) and New Orleans Emps.’ Ret. Sys. v. PACS Group, Inc., No. 24-cv-8882 (S.D.N.Y.) (“New Orleans”), Dkt. No. 1 (“New Orleans Compl.”). See Tulepan v. Roberts, 2014

WL 6808313, at *1 (S.D.N.Y. Dec. 3, 2014) (“For the purposes of resolving this motion to transfer venue, the Court accepts the allegations in the complaint as true.”). However, the Court may also “consider material outside of the pleadings.” Mohsen v. Morgan Stanley & Co. Inc., 2013 WL 5312525, at *3 (S.D.N.Y. Sept. 23, 2013). PACS is a Delaware corporation headquartered in Farmington, Utah. Manchin Compl. ¶ 16; New Orleans Compl. ¶ 29. PACS was founded in 2013. New Orleans Compl. ¶¶ 4, 22. It is one of the largest operators of skilled nursing facilities in the United States. Id. ¶¶ 4, 23. On March 13, 2024, PACS filed with the United States Securities and Exchange Commission (“SEC”) a registration statement on Form S-1 for an initial public offering (“IPO”) of its common stock. Id. ¶ 25. The registration statement was declared effective on April 10,

2024, and PACS filed the IPO prospectus with the SEC on April 12, 2024. Id.; Manchin Compl. ¶ 3. Pursuant to the registration statement, PACS sold 21,428,572 shares of its common stock to the public at a price of $21 per share for proceeds of $450 million. New Orleans Compl. ¶ 25; Manchin Compl. ¶ 3. PACS held a secondary public offering (“SPO”) of its stock in September 2024. New Orleans Compl. ¶ 26. On September 3, 2024, PACS filed with the SEC a registration statement for the SPO on Form S-1. Id. On September 6, 2024, it filed the prospectus for the SPO with the SEC. Id. Pursuant to the registration statement for the SPO, PACS sold 2,777,778 shares of common stock to the public at a price of $36.25 per share for proceeds of $589.3 million. Id. The Individual Defendants are officers and directors of PACS. Id. ¶¶ 30–31, 37–41; Manchin Compl. ¶¶ 17–18, 20–22. The Underwriter Defendants are financial services companies that served as the underwriters of the IPO and SPO. New Orleans Compl. ¶¶ 43–50; Manchin Compl. ¶¶ 24–32.

PACS’s IPO registration statement touted its business model to attract higher-acuity patients and its ability to acquire underperforming skilled nursing facilities and convert them to higher-acuity, high-value add short-term transitional care SNFs. New Orleans Compl. ¶¶ 55–56; Manchin Compl. ¶ 42. It also highlighted the steps PACS was taking to meet its compliance obligations. New Orleans Compl. ¶¶ 59–60; Manchin Compl. ¶ 43. The SPO registration statement made substantially the same claims, discussing the company’s culture of compliance and its multi-faceted growth strategy. New Orleans Compl. ¶¶ 72–74. In May 2024 and August 2024, PACS issued earnings releases and quarterly reports on Form 10-Q and conducted earnings calls in connection with the close of its first and second quarters of 2024. New Orleans Compl. ¶¶ 62–71. PACS reported that its results for each quarter

were “very strong” or “strong.” Id. On November 4, 2024, an investment research firm named Hindenburg Research released a report (the “Hindenburg Report”) alleging that PACS had engaged in improper practices, including manipulating Medicare billing through the misuse of a COVID-era waiver, which drove a significant portion of the company’s revenues, and inflating its Medicare revenue by inappropriately classifying lower-acuity patients as high-acuity skilled care patients, thereby securing higher reimbursement rates to bolster its financial performance. Manchin Compl. ¶¶ 4, 61; New Orleans Compl. ¶¶ 13, 76. The Hindenburg Report also accused PACS of billing for unnecessary treatments and for treatments that were never actually performed and of misrepresenting staffing levels and qualifications to regulators to meet minimum staffing requirements and increase facility ratings and state bonuses. Manchin Compl. ¶¶ 4, 61; New Orleans Compl. ¶ 76. On November 4, 2024, PACS’s share price dropped $11.93 per share, or 27 percent, to $31.01 per share (below its IPO and SPO price) in reaction to the release of the

Hindenburg Report. Manchin Compl. ¶¶ 5, 62; New Orleans Compl. ¶ 77. On November 6, 2024, PACS announced that it would delay the release of its third-quarter 2024 financial results while its Audit Committee was conducting an investigation and that it had received civil investigative demands from the federal government regarding its practices. Manchin Compl. ¶¶ 6, 63; New Orleans Compl. ¶ 78. On that news, PACS’s share price dropped $11.45 per share, or 38.8 percent, to close at $18.09 on November 6, 2024. Manchin Compl. ¶¶ 7, 64; New Orleans Compl. ¶ 79. PROCEDURAL HISTORY On November 13, 2024, an individual investor named Christopher Manchin filed a complaint in this Court against PACS, the Individual Defendants, and the Underwriter Defendants, alleging claims under Sections 11 and 15 of the Securities Act of 1933 and Section 10(b) and 20(a)

of the Securities Exchange Act of 1934 related to the IPO and PACS’s statements following the IPO. See generally Manchin Compl. Eight days later, the New Orleans Employees’ Retirement System filed a complaint in this Court against the same Defendants as well as UBS Securities alleging that false statements were made in the registration statement for the SPO and in PACS’s statements in connection with its quarterly reports. See generally New Orleans Compl. On January 7, 2025, the Court entered a stipulation and order consolidating the New Orleans and Manchin actions and setting a schedule for the filing of a consolidated complaint following the appointment of lead plaintiff and lead counsel. Dkt. No. 16.1 On January 13, 2025, competing motions to be appointed Lead Plaintiff and for appointment of Lead Counsel were filed. Dkt. Nos. 20, 23, 26. On February 11, 2025, the Court issued a memorandum and order appointing the 1199SEIU Health Care Employees Pension Fund (“Pension Fund” or “Lead Plaintiff”) as lead

plaintiff and its counsel Labaton Keller Sucharow LLP as counsel. Dkt. No. 39; Manchin v. PACS Grp., Inc., 2025 WL 460775 (S.D.N.Y. Feb. 11, 2025).

Free access — add to your briefcase to read the full text and ask questions with AI

Manchin v. PACS Group, Inc., (S.D.N.Y. 2025).

Manchin v. PACS Group, Inc. (Manchin v. PACS Group, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Gulf Oil Corp. v. Gilbert
330 U.S. 501 (Supreme Court, 1947)
Koster v. (American) Lumbermens Mutual Casualty Co.
330 U.S. 518 (Supreme Court, 1947)
Hoffman v. Blaski
363 U.S. 335 (Supreme Court, 1960)
Van Dusen v. Barrack
376 U.S. 612 (Supreme Court, 1964)
Penn-Central Merger & N & W Inclusion Cases
389 U.S. 486 (Supreme Court, 1967)
Phillips Petroleum Co. v. Shutts
472 U.S. 797 (Supreme Court, 1985)
Stewart Organization, Inc. v. Ricoh Corp.
487 U.S. 22 (Supreme Court, 1988)
In Re Genentech, Inc.
566 F.3d 1338 (Federal Circuit, 2009)
Forjone v. The State of California
425 F. App'x 73 (Second Circuit, 2011)
Calavo Growers Of California v. Generali Belgium
632 F.2d 963 (Second Circuit, 1980)
In Re Warrick
70 F.3d 736 (Second Circuit, 1995)
Blair & Co., Inc. v. Gottdiener
462 F.3d 95 (Second Circuit, 2006)
Shulof v. Westinghouse Electric Corporation
402 F. Supp. 1262 (S.D. New York, 1975)